Shyam Lal Mudavath

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8840099/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effervescent based nano-gas carrier enhanced the bioavailability of poorly aqueous soluble drug: A comprehensive mechanistic understanding. Journal of Drug Delivery Science and Technology, 2022, 69, 103167.	1.4	4
2	Carboxymethyl chitosan modified lipid nanoformulations as a highly efficacious and biocompatible oral anti-leishmanial drug carrier system. International Journal of Biological Macromolecules, 2022, 204, 373-385.	3.6	15
3	Fabrication, physicochemical characterization and In vitro anticancer activity of nerolidol encapsulated solid lipid nanoparticles in human colorectal cell line. Colloids and Surfaces B: Biointerfaces, 2022, 215, 112520.	2.5	9
4	Transport mechanism of hydroxy-propyl-beta-cyclodextrin modified solid lipid nanoparticles across human epithelial cells for the oral absorption of antileishmanial drugs. Biochimica Et Biophysica Acta - General Subjects, 2022, 1866, 130157.	1.1	5
5	Nanodiagnostics in leishmaniasis: A new frontiers for early elimination. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2021, 13, e1675.	3.3	12
6	Detection of latent fingerprints using luminescent Gd0.95Eu0.05PO4 nanorods. Journal of Rare Earths, 2021, , .	2.5	12
7	Downshifting and upconversion dual mode emission from lanthanide doped GdPO4 nanorods for unclonable anti-counterfeiting. Materials Today Communications, 2021, 26, 102144.	0.9	15
8	Coalition of Biological Agent (Melatonin) With Chemotherapeutic Agent (Amphotericin B) for Combating Visceral Leishmaniasis via Oral Administration of Modified Solid Lipid Nanoparticles. ACS Biomaterials Science and Engineering, 2021, , .	2.6	9
9	Formulation, characterization and in vitro anti-leishmanial evaluation of amphotericin B loaded solid lipid nanoparticles coated with vitamin B12-stearic acid conjugate. Materials Science and Engineering C, 2020, 117, 111279.	3.8	34
10	Recuperating Biopharmaceutical Aspects of Amphotericin B and Paromomycin Using a Chitosan Functionalized Nanocarrier via Oral Route for Enhanced Anti-leishmanial Activity. Frontiers in Cellular and Infection Microbiology, 2020, 10, 570573.	1.8	20
11	Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis. Scientific Reports, 2020, 10, 12243.	1.6	73
12	Sensible graphene oxide differentiates macrophages and <i>Leishmania</i> : a bio-nano interplay in attenuating intracellular parasite. RSC Advances, 2020, 10, 27502-27511.	1.7	7
13	Enkephalins as a therapeutic intervention for visceral leishmaniasis. Medical Hypotheses, 2020, 144, 109956.	0.8	3
14	Evaluation of Safety and Antileishmanial Efficacy of Amine Functionalized Carbon-Based Composite Nanoparticle Appended With Amphotericin B: An in vitro and Preclinical Study. Frontiers in Chemistry, 2020, 8, 510.	1.8	18
15	Improvising anti-leishmanial activity of amphotericin B and paromomycin using co-delivery in d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) tailored nano-lipid carrier system. Chemistry and Physics of Lipids, 2020, 231, 104946.	1.5	14
16	Envisioning the innovations in nanomedicine to combat visceral leishmaniasis: for future theranostic application. Nanomedicine, 2019, 14, 1911-1927.	1.7	27
17	Mannose-conjugated curcumin-chitosan nanoparticles: Efficacy and toxicity assessments against Leishmania donovani. International Journal of Biological Macromolecules, 2018, 111, 109-120.	3.6	57
18	An oral formulation of Amphotericin B for the treatment of visceral Leishmaniasis: f-Gr-AmB. International Journal of Infectious Diseases, 2016, 45, 367.	1.5	6

#	Article	IF	CITATIONS
19	Characterization and evaluation of amine-modified graphene amphotericin B for the treatment of visceral leishmaniasis: in vivo and in vitro studies. Drug Design, Development and Therapy, 2014, 8, 1235.	2.0	20
20	In Vivo Assessment of Antileishmanial Property of 4-(4,4,8-Trimethyl-7-) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 707	Td (oxo-3-ox	-oxabicyclo
	Drug Design and Discovery, 2014, 11, 937-939.	0.4	5
21	Comparative Evaluation of Blood and Serum Samples in Rapid Immunochromatographic Tests for Visceral Leishmaniasis. Journal of Clinical Microbiology, 2013, 51, 3955-3959.	1.8	12